Savara Inc (NASDAQ:SVRA – Free Report) – Equities research analysts at HC Wainwright lowered their FY2029 earnings per share (EPS) estimates for shares of Savara in a research note issued to investors on Wednesday, May 28th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of $0.08 for the year, down from their prior forecast of $0.14. HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share.
SVRA has been the topic of several other research reports. Guggenheim reissued a “buy” rating and set a $8.00 target price (down previously from $9.00) on shares of Savara in a research report on Wednesday. Evercore ISI cut their target price on Savara from $3.00 to $2.00 and set an “in-line” rating on the stock in a research report on Wednesday. Finally, Wells Fargo & Company cut their target price on Savara from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Wednesday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.17.
Get Our Latest Stock Analysis on Savara
Savara Price Performance
Shares of NASDAQ SVRA opened at $2.29 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $5.11. The firm has a market capitalization of $395.80 million, a PE ratio of -5.33 and a beta of 0.44. The stock’s 50-day simple moving average is $2.92 and its 200-day simple moving average is $2.94.
Savara (NASDAQ:SVRA – Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12).
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new position in Savara during the 4th quarter worth approximately $33,000. XTX Topco Ltd purchased a new position in Savara during the 4th quarter worth approximately $34,000. Ameriprise Financial Inc. purchased a new position in Savara during the 4th quarter worth approximately $37,000. KLP Kapitalforvaltning AS purchased a new position in Savara during the 4th quarter worth approximately $41,000. Finally, Hsbc Holdings PLC purchased a new position in Savara during the 4th quarter worth approximately $48,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.
Savara Company Profile
(Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
See Also
Receive News & Ratings for Savara Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Savara and related companies with MarketBeat.com’s FREE daily email newsletter.
